Prenetics Raises IM8 Revenue Guidance After 6x YoY Growth
Event summary
- Prenetics reported Q1 2026 revenue of $36.0M, with IM8 revenue growing nearly 6x YoY to $33.8M.
- Full-year 2026 IM8 revenue guidance raised to $190M–$210M from $180M–$200M.
- Q2 2026 revenue projected at $46M–$48M, with IM8 contributing $44M–$46M, representing ~33% sequential growth.
- Company divested digital assets for $41.3M in proceeds, boosting cash balance to ~$91.3M as of May 13, 2026.
- Appointed Brian J. Rosin as Chief Financial Officer of IM8.
The big picture
Prenetics' IM8 brand is demonstrating strong global traction, with accelerating revenue growth and expanding gross margins. The company's strategic focus on quarterly subscriptions and international expansion positions it well in the competitive consumer health market. The divestment of digital assets and share buyback program reflect a disciplined approach to capital allocation amid rapid scaling.
What we're watching
- Product Expansion
- IM8's planned Q4 2026 launches in hydration, creatine, and kids’ gummies could broaden its addressable market and drive further revenue diversification.
- International Growth
- IM8's expansion into 43 countries, with over 60% of revenue generated outside the U.S., will be a key driver of its global scaling strategy.
- Subscription Model
- The shift to quarterly subscription plans has significantly increased average order value, which will be critical for sustaining cash flow and customer lifetime value.
Related topics